Adam R Craig - Net Worth and Insider Trading
Adam R Craig Net Worth
The estimated net worth of Adam R Craig is at least $267,610 dollars as of 2024-12-26. Adam R Craig is the President and CEO of CTI BioPharma Corp and owns about 29,440 shares of CTI BioPharma Corp (CTIC) stock worth over $267,610. Details can be seen in Adam R Craig's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Adam R Craig has not made any transactions after 2023-01-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Adam R Craig
Adam R Craig Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Adam R Craig owns 3 companies in total, including CTI BioPharma Corp (CTIC) , Sunesis Pharmaceuticals Inc (SNSS) , and Viracta Therapeutics Inc (VIRX) .
Click here to see the complete history of Adam R Craig’s form 4 insider trades.
Insider Ownership Summary of Adam R Craig
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CTIC | CTI BioPharma Corp | 2023-01-24 | director & President and CEO |
SNSS | Sunesis Pharmaceuticals Inc | 2015-02-27 | EVP & Development & CMO |
VIRX | Viracta Therapeutics Inc | 2012-02-27 | EVP & Development & CMO |
Adam R Craig Latest Holdings Summary
Adam R Craig currently owns a total of 1 stock. Adam R Craig owns 29,440 shares of CTI BioPharma Corp (CTIC) as of January 24, 2023, with a value of $267,610.
Latest Holdings of Adam R Craig
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
CTIC | CTI BioPharma Corp | 2023-01-24 | 29,440 | 9.09 | 267,610 |
Holding Weightings of Adam R Craig
Adam R Craig Form 4 Trading Tracker
According to the SEC Form 4 filings, Adam R Craig has made a total of 7 transactions in CTI BioPharma Corp (CTIC) over the past 5 years, including 2 buys and 5 sells. The most-recent trade in CTI BioPharma Corp is the sale of 85,317 shares on January 24, 2023, which brought Adam R Craig around $511,902.
Insider Trading History of Adam R Craig
- 1
Adam R Craig Trading Performance
GuruFocus tracks the stock performance after each of Adam R Craig's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Adam R Craig is 68.4%. GuruFocus also compares Adam R Craig's trading performance to market benchmark return within the same time period. The performance of stocks bought by Adam R Craig within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Adam R Craig's insider trading performs compared to the benchmark.
Performance of Adam R Craig
Adam R Craig Ownership Network
Adam R Craig Owned Company Details
What does CTI BioPharma Corp do?
Who are the key executives at CTI BioPharma Corp?
Adam R Craig is the director & President and CEO of CTI BioPharma Corp. Other key executives at CTI BioPharma Corp include EVP & Chief Commercial Officer James K Fong , EVP & Chief Financial Officer David Kirske , and other: See Explanation of Responses Biotechnology Value Fund L P .
CTI BioPharma Corp (CTIC) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of CTI BioPharma Corp (CTIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CTI BioPharma Corp (CTIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
CTI BioPharma Corp (CTIC)'s detailed insider trading history can be found in Insider Trading Tracker table.
CTI BioPharma Corp Insider Transactions
Adam R Craig Mailing Address
Above is the net worth, insider trading, and ownership report for Adam R Craig. You might contact Adam R Craig via mailing address: C/o Innovive Pharmaceuticals, Inc., 555 Madison Avenue, 25th Floor, New York Ny 10022.